Perkins researcher elected as prestigious new Fellow
The Translational Cancer Research Program is focused on developing key infrastructure to provide a pipeline to translate laboratory discoveries into new cancer treatments and medicines. We have established the Perkins Cancer Biobank and are collecting tumour samples from hard-to-treat cancers in collaboration with Surgeons, Oncologists and Pathologists across several Perth hospitals. These samples are being analysed using state of the art omics technologies (including genomics, single cell sequencing, metabolomics, proteomics) to provide detailed molecular characterisation of individual cancers. We are also developing preclinical models including cancer organoids, slice cultures and improved in vivo laboratory models to evaluate immunotherapy drugs more accurately. These models are being used to assess new treatments as well as new combination therapies.
This infrastructure will facilitate improved preclinical assessment of new cancer medicines, resulting in greater success rates for clinical trials and better outcomes for cancer patients. In addition, these data will advance the development of novel biomarkers needed to better monitor pharmacodynamics, predict response and resistance to specific drugs as well as enable better stratification of target populations.
I. Perkins Cancer Biobank
II. Patient derived organoids and slice cultures
III. In vivo preclinical cancer models